The Impact of Mass Drug Administration on Lymphatic Filariasis

Table 3

Percentage microfilaria prevalence reduction at mid-term and pretransmission assessment survey (pre-TAS) compared to baseline prevalence in LF mass drug administration.

Reference, country	Baseline Mf prevalence (N)	LF prevalence (N); % PR
		Mid-term Mf	Pre-TAS Mf
[16], Egypt	11.50 (1000)	—	0.20 (1000); 98.26
[17], Sierra Leone	2.60 (8233)	0.30 (6023); 88.54	—
[18], Sierra Leone	2.60 (8233)	—	0.54 (4230); 79.23
[20], Egypt	14.60 (1877)	—	1.20 (1828); 91.78
[21], India	4.53 (14963)	0.06 (6649); 98.66	—
[19], Nigeria	4.91 (4198)	—	0.87 (1720); 82.28
[22], Tanzania	24.48 (919)	10.10 (674); 58.74	—
[24], Tanzania	24.48 (919)	—	2.80 (393); 88.56
[25], Tanzania	24.48 (919)	—	33.33 (60); ^†36.15
[26], Indonesia	8.91 (2165)	0.28 (1776); 96.86	—
[27], Papua New Guinea	14 (757)	1.32 (529); 90.57	—

Mf: microfilaria; LF: lymphatic filariasis; N, sample size; pre-TAS: pretransmission assessment survey; % PR, percentage prevalence reduction compared to baseline prevalence; —: no data available; ^†increase in prevalence.